| Alzheimer Disease |
1 |
1 |
| Aducanumab |
0 |
0.98 |
| Food and Drug Administration (FDA) |
0 |
0.5 |
| Social Determinants of Health |
0 |
0.33 |
| Mild Cognitive Impairment |
0 |
0.2 |
| Brain |
0 |
0.17 |
| Health Care Quality, Access, and Evaluation |
0 |
0.17 |
| Dementia |
0 |
0.14 |
| Medicare |
0 |
0.14 |
| Outpatient Clinic |
0 |
0.14 |
| California |
0 |
0.12 |
| Cognitive Impairment |
0 |
0.1 |
| Magnetic Resonance Imaging (MRI) |
0 |
0.1 |
| Nevada |
0 |
0.1 |
| Ohio |
0 |
0.1 |
| Clinical Research |
0 |
0.07 |
| Impairment |
0 |
0.07 |
| Patient Safety |
0 |
0.07 |
| Positron Emission Tomography (PET) |
0 |
0.07 |
| Scan |
0 |
0.07 |
| Biologic Therapy |
0 |
0.05 |
| Edema |
0 |
0.05 |
| Intravenous (IV) |
0 |
0.05 |
| Memory |
0 |
0.05 |
| Multiple Sclerosis |
0 |
0.05 |
| Other Specialty |
0 |
0.05 |
| Preventive Screening |
0 |
0.05 |
| Thyroid Disease |
0 |
0.05 |
| Adverse Effects |
0 |
0.02 |
| Amyloid Plaque |
0 |
0.02 |
| Biomarker |
0 |
0.02 |
| Central Nervous System |
0 |
0.02 |
| Child |
0 |
0.02 |
| Drug Development |
0 |
0.02 |
| Emesis |
0 |
0.02 |
| Hospital |
0 |
0.02 |
| Medicaid |
0 |
0.02 |
| Minnesota |
0 |
0.02 |
| Monoclonal Antibody |
0 |
0.02 |
| Nurse Practitioners |
0 |
0.02 |
| Primary Care |
0 |
0.02 |
| Social Media |
0 |
0.02 |
| Thyroid |
0 |
0.02 |
| Triage |
0 |
0.02 |